Anticoagulants Flashcards

1
Q

2 main types of Heparin

A

-Unfractionated ‘standard’
-Low Molecular Weight

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are anticoagulant drugs?

A

-Anticoagulant drugs interfere with secondary haemostasis (i.e.
coagulation factors).
-We tend to distinguish them from antiplatelet drugs or thrombolytic therapies.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the different kinds of anticoagulants?

A

-Oral: Warfarin/ DOACs
-Parental: Heparin (UFH), LMWH, Penta saccharides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Antiplatelets vs anticoagulants

A

-Antiplatelet medications are of greater efficacy in arterial thromboses than venous thromboembolism (platelets play a greater role in thrombosis due to ‘shear stress’ in arterial flow).
=Used in acute coronary syndromes and ischaemic
cerebrovascular diseases.
-Anticoagulants can be used for both arterial and venous thromboses.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are Heparins?

A

-Heparins are glycosaminoglycans which act as anticoagulants.
- Heparin can be given parenterally as unfractionated heparin (UFH, bolus and continuous IV infusion/ subcutaneous) or low molecular weight heparin (LMWH- subcutaneously once daily).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Heparins mechanism of action

A

-Potentiates action of antithrombin (AT): a naturally circulating anticoagulant which itself inhibits Factor Xa and thrombin
=Binding of pentsaccharide sequence (AT and Xa) induces conformational change

-UFH: enhanced AT effect on FXa and thrombin
-LMWH: Greater effect on FXa but less on thrombin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Heparins mechanism of action

A

-Potentiates action of antithrombin (AT): a naturally circulating anticoagulant which itself inhibits Factor Xa and thrombin
=Binding of pentsaccharide sequence induces conformational change

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Main use of LMWH

A

-PE
-DVT
-Acute Coronary Syndrome
-Thromboprophylaxis (not in renal failure)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Monitoring and reversal of UFH

A

-Infusions monitored and adjusted using APTT every 4-6 hrs (daily once stable)
-Half-life short (100 minutes) so high APTT managed by stopping heparin
=Good for where rapid reversibility required (high bleeding risk, severe renal failure)
-Protamine (sulphate) reverses effect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Monitoring and reversal of LMWH

A

-Due to predictable bioavailability, monitoring rarely required
-Anti-Xa assay used instead of unreliable APTT here
-Reversal with protamine but only achieves 60%
-Half-life 4 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Complications of Heparins

A

-Bleeding
-Heparin Induced Thrombocytopenia
-Osteoporosis in prolonged use
=Rarer in LMWH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe Heparin Induced Thrombocytopenia (HIT)

A

-Immune mediated reaction
-Develops at 5-10 days of treatment
-Prothrombotic condition
-Use a non-heparin anticoagulant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Mechanism of Warfarin

A

-Vitamin K antagonist
=Prevents Vitamin K recycling
=Reduced rate of synthesis of factors
=Takes 5 days as pre-existing factors remain (pro-thrombotic first few days as depletes natural anticoagulants faster than factors= can cause skin and soft tissue necrosis so cover with LMWH/ slow initiation)

-Reduces factors 2,7,9,10 (and natural anticoagulants Protein C and Protein S)
-Acts on extrinsic pathway

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Main uses of Warfarin

A

-DVT
-PE
-AF
-Artificial heart valves
-Rheumatic HD
-Cardioversion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Monitoring of warfarin

A

-INR (international normalised ratio)- universal standard for corrected PT time (ratio of PT time to population average)
-Normal= 1
-Target 2-3 sometimes higher in indication and individuals

=Regular blood tests to adjust level

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Dosing of Warfarin

A

-Warfarin metabolised by CYP450 system
=many drugs, intercurrent illness and diet/alcohol can interfere
=Increase INR (enzyme inhibitor), low INR (enzyme inducers= anti-epileptics)

-Omeprazole, erythromycin, cranberry juice increase effect of warfarin

=Appropriate counselling

17
Q

High INR problems

A

-Haemorrhage (brain and bowel)
-Teratogenic (early pregnancy)
-Soft tissue necrosis

18
Q

High INR problems

A

-Haemorrhage
-Teratogenic
-Soft tissue necrosis

19
Q

Management for minor bleeding on warfarin/ INR>8

A
  1. Stop warfarin
  2. Oral or IV vitamin K (1-2mg)
  3. Re-introduce at a lower dose when bleeding resolves
20
Q

Management for serious bleeding on warfarin/ INR>1.1

A
  1. Stop warfarin
  2. IV vitamin K (5-10mg)
  3. Prothrombin complex concentrate (Beriplex)
21
Q

Groups of DOACs

A

-Direct thrombin inhibitors
=Dabigatran

-Factor Xa inhibitors
=Apixaban
=Rivaroxaban
=Edoxaban

22
Q

Main uses of DOAC

A

-VTE prophylaxis after knee and hip replacement and treatment
-AF (non-valvular)
-Acute coronary syndrome

23
Q

Disadvantages of DOAC

A

-Unsafe in advanced renal impairment
-Not as effective as warfarin for metallic heart valves
-Bleeding
-Reversal agents pending

24
Q

Disadvantages of DOAC

A

-Unsafe in advanced renal impairment
-Not as effective as warfarin for metallic heart valves
-Bleeding
-Reversal agents pending (Idarucizumab for dabigatran)

25
Q

Reversal agents for DOAC

A

-Idarucizumab for dabigatran
-Andexanet Alpha: Xa inhibitors
-Ciraparantag: Dabigatran and Xa inhibitors